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Abstract 
Colorectal cancer is the 2nd deadliest cancer in the US with more than 50,000 deaths 
in 2017.  Our group has identified KCNQ1 and CFTR as colorectal cancer tumor 
suppressors. KCNQ1-low as well as CFTR-low expressing tumors have significantly 
poorer prognosis than high expressers: KCNQ1-low in stages II, III and IV colorectal 
cancer; CFTR-low in stage II.  Thus, it is important to understand how KCNQ1 and CFTR 
are downregulated in these poor prognosis cancers.  KCNQ1 and CFTR are expressed at 
the base of the intestinal crypt, the site of the stem cell compartment and origin of colorectal 
cancer.  The Wnt/ β-catenin signaling pathway is important in determining stemness and 
is dysregulated in >85% of human colon cancers.  Therefore, I am testing two hypotheses 
involving Wnt/ β-catenin and these tumors suppressors: 1) KCNQ1 is regulated through a 
putative enhancer region containing a β-catenin binding site and 2) KCNQ1 and CFTR 
regulate β-catenin activity.   
Our putative enhancer region was identified through a survey of the KCNQ1 
genomic sequence for eQTLs (SNPs associated with altered expression of KCNQ1) which 
identified SNP rs2283155 in KCNQ1 intron 2.  SNPs are markers for potential polymorphic 
variants associated with altered gene expression.  The enhancer region includes the SNP 
rs2283155, a TCF7L2 binding site (the binding partner of transcriptionally active β-
catenin) and a larger DNase I hypersensitivity enhancer region.  Luciferase reporter assays 
showed regulation by our enhancer region of a reporter gene.  Follow-up data has suggested 
that KCNQ1 is the gene being regulated.   
 Second, to investigate the effect of Kcnq1 and Cftr on β-catenin signaling, I am 
examining β-catenin in organoids, a well-established model of the stem cell compartment. 
i ii 
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Activation of β-catenin is characterized by its movement from the cytoplasm or membrane 
to the nucleus.  I developed an immunofluorescence assay to quantitatively measure 
nuclear β-catenin localization in Kcnq1 deficient/expressing and Cftr deficient/expressing 
organoids.  These organoids had increased β-catenin activity in Kcnq1-deficient and Cftr-
deficient organoids, suggesting a mechanism for tumor suppressor activity of Kcnq1 and 
Cftr.  This work may provide insight into the role of Kcnq1 and Cftr within the cellular 
environment and potential ways to manipulate their expression to improve survival. 
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Introduction 
Colorectal Cancer 
 Across the globe, colorectal cancer is the second most common cancer, with more 
than 1.8 million cases reported in 2018 alone (World Cancer Research Fund). In the 
United States, colorectal cancer is estimated to affect more than 140,000 people and will 
kill more than 50,000 this year (NIH 2018).  8.1% of all new cancer cases and 8.3% of 
cancer deaths are due to colorectal cancer (NIH 2018).  This is a very significant 
percentage when one considers the many different types of cancers that exist.  From 1992 
to 2015, both the incidence and mortality of colorectal cancer have decreased, however, 
the number of people affected still remains troublingly high (Figure 1).   
 There are several possible reasons for the high mortality rate.  Many cases of 
colorectal cancer are not detected until later stages, and prognosis for these patients is 
significantly worse (Siegel et al., 2017).  Another problem is that certain cases of 
colorectal cancer have worse prognosis compared to other cases at the same clinical stage 
(Taieb et al., 2017).  Many biomarkers have been identified to help predict colorectal 
Figure 1: Incidence and mortality rates of colorectal cancers from 1992 to 
2015.  New cases are in light green, deaths are in dark green. NIH, 2015.   
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cancer prognosis (Bramsen et al., 2017).  Biomarkers are genes whose expression is 
associated with cancer.  More biomarkers are necessary to determine cancer 
aggressiveness and to assist with earlier detection of colorectal cancer.  Most importantly, 
some biomarkers play a causal role as well as a diagnostic role, and the identification of 
such genes is beneficial for the development of therapeutic targets.  
 Colorectal cancers are either sporadic or hereditary.  Within these broader 
categories, there are two types, MSS (microsatellite stable) or MSI (microsatellite 
instable).  Microsatellites are long, sequence repeats with high mutation rates when the 
DNA mismatch repair mechanism is not functional (Fleming, Ravula, Tatishchev, & 
Wang, 2012).  MSI colorectal cancers’ microsatellite regions vary in length, while MSS 
colorectal cancers microsatellite regions do not (Fleming et al., 2012).  MSI colorectal 
cancers make up about 15% of all sporadic colorectal cancers, and nearly all hereditary 
colorectal cancers (Xiao & Freeman, 2015).  MSI type patients have longer disease-free 
survival as well as overall survival (Hong et al., 2012).  Moreover, the MSI type of 
colorectal cancer is the only type that responds significantly to immunotherapy 
treatments (Kather, Halama, & Jaeger, 2018).  Immunotherapy is a process of modifying 
the immune system to recognize and fight cancer cells which has proved very promising 
in many different types of cancer (Duong, 2014).  However, MSS colorectal cancer, 
making up the other 85% of all sporadic colorectal cancers, is the more aggressive form 
of colorectal cancer, and remains unresponsive to most immunotherapies.   
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Intestinal Structure and Signaling pathways   
 Colorectal cancer develops in the epithelial layer of the gastrointestinal tract.  The 
epithelial layer of the intestine is comprised of a single layer of cells.  In the small 
intestine, there are structures called villi which protrude toward the center of the intestine 
(Figure 2).  Villi are formed by cellular proliferation within the crypt, causing outward 
migration of those cells.  These villi greatly increase the surface area of the small 
intestine increasing absorption of nutrients.  There are also invaginations of the epithelial 
tissue that enfold away from the lumen of the intestine, forming small crypt structures.  
The colon has crypts; however, they do not have villi.   
These crypts provide protection to the stem cells located at the base.  Stem cells 
are vital for the regeneration of the epithelial tissue through the process of stem cell 
Figure 2: Structure of small intestinal (left) and colon epithelial tissue (right). 
Both have crypt structures, where the stem cells are located.  However, the 
small intestine has villi structures which extend into the intestinal lumen, 
while the colon does not. Reya and Clevers, 2005.  
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differentiation.  This process occurs approximately every seven days (Reya & Clevers, 
2005), beginning with stem cells at the base of the crypt, usually about six stem cells in 
total (Reya & Clevers, 2005).  Following asymmetric cell division, stem cells produce 
daughter cells that differentiate into a set of cells referred to as the proliferative 
progenitors, enterocyte progenitors, or transit amplifying cells (Tettah et al., 2016; Flier 
& Clever, 2009; Haegebarth & Clevers, 2009).  From this intermediate form, the cells 
differentiate into their final form: either goblet cells, enteroendocrine cells, secretory 
enterocytes, or absorptive enterocytes (Flier & Clevers, 2009).  As the cells differentiate, 
they move upward until they reach the top of the crypts, where they are sloughed off into 
the epithelial lumen.  There is a rapid turnover of epithelial tissue, as the intestinal 
environment is very harsh.  Until recently, it was thought that this stem cell 
differentiation pathway could only progress in the one direction, however, recent studies 
have found that dedifferentiation of intestinal cells back into stem cells can occur 
(Schwitalla et al.,2013; et al.,2016).  
Figure 3: Intestinal stem cell compartment and differentiated epithelial 
cells Anderson et al., 2011.  
Secretory cell 
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 Intestinal stem cells are known to express the LGR5 gene, a Wnt target gene 
encoding a transmembrane protein (Zeuner et al.,2014; Haegebarth & Clevers, 2009).  
These stem cells have “stemness”, or an ability to self-renew and differentiate into a 
varied subset of cells (Zeuner et al.,2014).  There are two subpopulations of stem cells: 
crypt base cells and +4 cells.  The crypt base cells are marked by the LGR5 stem cell 
marker, and are in an active state (Barker et al., 2007).  These crypt base cells also 
commonly express Ki67, a cellular marker for proliferation (Barker et al.,2007).  The 
LGR5+ stem cells are rapidly dividing, but they divide much more slowly in the colon 
than in the small intestine (Barker et al.,2007).    
The other subpopulation of stem cells that do not express the LGR5 gene are 
classified as the 4+ LRC stem cells (Barker et al.,2007; (Umar, 2010).  These cells are so 
named because they are found at position 4 in the intestinal crypt.  These 4+ cell express 
specific stem cell markers, including DCAMKL-1, Bmi1, Msi1, BmpR1a, mTERT 
(Umar, 2010).  While the LGR5+ cells are constantly dividing, the 4+ cells do not 
undergo rapid cell division.  They are normally quiescent, or in a dormant state (Umar, 
2010).  These +4 stem cells are suspected to be a reservoir for renewing both the 
intestinal epithelial cells and the intestinal stem cells (Kabiri 2018; Beumer & Clevers, 
2016).        
 The characteristics of stem cells are controlled by many signaling pathways, the 
most important being the Wnt/ β-catenin pathway.  The canonical Wnt/ β-catenin 
regulatory pathway (Figure 4) is one of the most influential pathways in the intestinal 
crypt, affecting the dynamics of the crypt, the stem cells, and influencing the 
development of colorectal cancer (Clevers, 2006).   There are also two noncanonical Wnt 
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receptor pathways: the Wnt/PCP pathway and the Wnt/Ca2+ pathway (Zhan, Rindtorff, 
& Boutros, 2017).  
In colorectal cancer, the canonical Wnt/ β-catenin is known to play a significant 
role (Clevers, 2006; Zhan, Rindtorff, & Boutros, 2017).  Wnt is a regulatory ligand 
protein, released by secretory cells within the intestinal crypt.  It binds to the 
transmembrane protein Frizzled, which is complexed with LPR (low-density lipoprotein 
receptor-related protein) and several other proteins (Nusse & Clevers, 2017).  The 
binding of Wnt triggers the release of β-catenin from the destruction complex, a major 
factor of which is the APC (adenomatous polyposis coli) protein (Zhan, Rindtorff, & 
Boutros, 2017).  This leaves the β-catenin protein in the cytoplasm available for 
translocation into the nucleus.  Inside the nucleus, the β-catenin acts as a transcription 
factor, binding to a TCF factor, causing its derepression and inducing expression of 
proliferation genes (Zhan, Rindtorff, & Boutros, 2017).  β-catenin also induces the 
expression of genes which maintain stemness of the stem cell (He et al., 2004).  Another 
Figure 4: Canonical Wnt/ β-catenin pathway. Nusse & Clevers, 2017. 
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important gene induced by the Wnt/ β-catenin pathway is LGR5.  LGR5 is a receptor for 
R-spondin, a secreted protein that induces the Wnt/ β-catenin pathway (de Lau et al., 
2011).    
 This pathway regulates the intestinal stem cells through a precise gradient of Wnt 
throughout the crypt (Reya 2005).  The highest Wnt/ β-catenin activity is observed at the 
base of the crypt, indicated by the high expression Wnt target proteins (Flier & Clevers, 
2009).  The Wnt/ β-catenin pathway determines whether the epithelial cells of the crypt 
are going to proliferate or differentiate (Flier & Clevers, 2009).  High Wnt/ β-catenin 
signaling induces higher proliferation, while lower induces differentiation (Flier & 
Clevers, 2009).  If Wnt is not present in the cellular environment, cell proliferation is 
halted, and the crypt epithelium will die off (Mah, Yan, & Kuo, 2016).  If Wnt is 
overexpressed throughout the crypt, over proliferation occurs (Flier & Clevers, 2009).  
The cells most exposed to Wnt/ β-catenin are the stem cells.  These are the only cells to 
have significant β-catenin staining in the crypt in a non-cancer situation (Flier & Clevers, 
2009).  In colorectal cancer, the canonical Wnt/ β-catenin pathway is known to play a 
significant role (Clevers, 2006; Zhan, Rindtorff, & Boutros, 2017).  If the regulation of 
Wnt/ β-catenin is lost, it has very serious consequences.  The Wnt/ β-catenin pathway is 
dysregulated in 85% of all sporadic colorectal cancers.   
Another important pathway in stem cell maintenance is the Notch pathway, which 
also plays a major role in the fate of cells after differentiation from the stem cell state 
(Flier & Clevers, 2009).  The Notch pathway helps to balance the proliferation and 
differentiation of cells within the intestine (Sancho, Cremona, & Behrens, 2015).  The 
Notch pathway involves interaction between two membrane spanning proteins on 
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adjacent cells, a receptor, known as Notch, and a ligand, known as Delta or Jagged.   The 
Notch receptor first binds to a Notch ligand, which results in cleaving of the receptor 
(Sancho, Cremona, & Behrens, 2015).  This leaves the intracellular portion of the Notch 
receptor (NICD) available in the cytoplasm to localize to the nucleus (Flier & Clevers, 
2009).  Once in the nucleus it binds to the transcription factor RBP-J to activate Notch 
target genes (Sancho, Cremona, & Behrens, 2015).  The target genes include HES1, 
which prevents expression of MATH1.  MATH1 expression is necessary for the 
differentiation of the secretory cells (Flier & Clevers, 2009).  When HES1is expressed 
instead of MATH1, the cells differentiate into absorptive enterocytes (Flier & Clevers, 
2009).   
The TGF-β pathway also plays an important role in homeostasis in the intestinal 
crypt environment, through its regulation of fibrosis and immune response modulation.  
The TGF-β is expressed in a gradient throughout the crypt, with higher expression 
towards the top of the crypt and lower expression toward the bottom (Cammareri et al., 
2017).  This is the opposite of the Wnt/ β-catenin pathway.  TGF-β proteins act through 
the SMAD pathway.  TGF-β first binds to the complexed receptors BMPR1 and BMPR2 
(Cammareri et al., 2017).   BMPR2 phosphorylates the BMPR1 receptor, which then 
phosphorylates the bound SMADs (R-Smad) factor (Katz et al., 2016).  SMADs then 
binds to SMAD4, and this complex moves into the nucleus, where it can act as either an 
activator or a repressor of specific target genes (Spit et al., 2018).  Some of the target 
genes include E-cadherin, collagen, and integrins; this SMAD complex has also been 
observed to interact with RUNX, a tumor suppressor gene (Katz et al., 2016).   
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Together, these pathways play a vital role in the maintenance and regulation of 
the stem cell compartment.  These intestinal stem cells in turn maintain the crypt, 
providing new cells that are continually lost to the harsh intestinal environment.  
Intestinal stem cells are essential to regenerate the healthy intestinal epithelium, but 
because of this capacity when dysregulated they can become cancer stem cells.  
 
Cancer Stem Cells in Colorectal Cancer 
Cancers are extremely heterogeneous, containing many different types of cells, 
and continually evolve in response to changes in their environment (Kreso & Dick, 
2014).  Many models have been developed to try to explain how cancers evolve.  The 
somatic evolution model suggests that a mutant tumor cell has a growth advantage and 
outcompetes the other surrounding cells (Greaves & Maley, 2012).  However, that model 
doesn’t full explain some dynamics of  tumor development, such as the presence of a 
small population of cells with variable proliferation and tumorigenesis properties (Chen, 
Dong, Haiech, Kilhoffer, & Zeniou, 2016).  These subpopulations of cells are called 
cancer stem cells.   
Cancer stem cells may have plasticity, the ability to transition from highly 
oncogenic states to lesser oncogenic states and back again (Cabrera, Hollingsworth, & 
Hurt, 2015).  This plasticity allows for even greater adaptability within tumors (Cabrera, 
Hollingsworth, & Hurt, 2015).  Intestinal stem cells and progenitor cells are able to 
transition to into cancer stem cells.  This produces a highly dynamic intestinal tumor 
which can adapt rapidly to its environment (Zeuner et al., 2014).   
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The presence of cancer stem cells has significant consequences for cancer 
treatments.  Cancer stem cell quiescence can lead to resistance to cancer therapies, many 
of which target the highly proliferative cancer cells of a tumor (Zeuner et al., 2014; Chen 
et al., 2016).  This resistance to therapy causes many cancer reoccurrences (Takeda et al., 
2018).  The plasticity of these cancer cells provides yet another avenue of treatment 
resistance.  If the cancer stem cells do happen to be removed by a cancer treatment, other 
cells can transition into cancer stem cells, making it very difficult to completely remove 
the cancer.  
 
Development of Colorectal Cancer  
 Colorectal cancer advances through several stages of development.  These stages 
are defined by several factors: size of tumor, depth of invasion through the various tissue 
layers of the intestine, and whether the tumor has spread from its original location (Figure 
5; ACS, 2018) . Stage 0 is the earliest stage of the cancer, whereupon the cancer has not 
Figure 5: Survival percentage after five years for each stage of colorectal 
cancer. Prognosis remains relatively high in the early stages but decreases in 
more advanced stage II and III decreases drastically in stage IV. ACS 2018. 
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extended deeper than the inner layer, or the mucosa of the colon (Figure 5; ACS, 2018).  
Stage I colorectal cancer has invaded through the mucosal layer, but not farther (Figure 5; 
ACS, 2018).  Stage II colorectal cancer has grown into all layers of colon (Figure 5; 
ACS, 2018).  Stage III colorectal cancers have grown into all layers of colon as well as 
invaded several nearby lymph nodes (Figure 5: ACS 2018).  Stage IV colorectal cancers 
have metastasized from the original tumor to distant organs or the peritoneum (Figure 5; 
ACS, 2018).  Mortality is the highest in the later stages of colorectal cancer (Siegel et al., 
2017).  Approximately 20% of colorectal cancer patients have metastasized cancer upon 
diagnosis (Riihimäki et al., 2016) .  Survival of most colorectal cancer patients with 
metastases is only 30 months after diagnosis (Fakih, 2015).   
 
Accumulation of Mutations in Colorectal Cancer  
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 As colorectal cancer develops, mutations accumulate in the tumors, leading to 
progression of the disease (Figure 6).  The Vogelstein lab identified the most common 
mutations and associated them with different stages of colorectal cancer (Vogelstein and 
Fearon, 1990).  One of the most commonly mutated genes was APC.  Mutations in APC 
occur in 85% of sporadic colorectal cancers (Valkenburg, Graveel, Zylstra-Diegel, 
Zhong, & Williams, 2011) Inactivation of APC promotes the development of adenomas 
and maintains tumor development (Dow et al., 2015). Mutations in KRAS (a gene 
responsible for cell proliferation regulation also) were found in about 40% of tumors.   
Mutations in KRAS promote the development of an early adenoma to a larger late stage 
adenoma. Other mutations, including p53 and BRAF commonly occur, pushing the 
adenoma to an invasive carcinoma (Senevitatne 2014; (Rao & Yamada, 2013).   
 However, these mutations do not explain every aspect of colorectal cancer 
development.  Vogelstein sequenced the exons of human colorectal cancer tumors, and 
found many mutations in each tumor (Fearon & Vogelstein, 1990).  The challenge then 
becomes determining which of these mutations have a functional role in colorectal 
cancers.  
 
Identification of Tumor Suppressor Gene KCNQ1  
 Forward genetic screens have been used to identify genes that are functionally 
important for development of colorectal cancer. A Sleeping Beauty (SB) transposon 
mutagenesis screen is a common tool for determining which mutations occur commonly 
in tumors (Starr et al., 2009).  A transposon is a segment of DNA that possesses the 
ability to move and replicate itself within the chromosome (Izsvák & Ivics, 2004).  
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Transposons are used as a tool for germ-line mutagenesis, the creation of mutations 
throughout the DNA (Izsvák & Ivics, 2004) .  The phenotype of mutated organisms is 
then evaluated. This allows researchers to determine which genes are responsible for a 
particular biological function (Nolan, Kapfhamer, & Bućan, 1997) .   
 To determine which genes may be playing a significant role in the development of 
colorectal cancer, a Sleeping Beauty transposon mutagenesis screen was done to generate 
mutations in a wild-type background  (Starr et al., 2009).  Transgenic mice were 
generated that carried a Sleeping Beauty transposon, a conditionally activated Sleeping 
Beauty transposase and a recombinase (Villin-Cre) to activate the transposase in the 
intestinal epithelium.  Unlike wild-type mice, mice carrying these alterations developed 
intestinal tumors. The mice were sacrificed, dissected, and tumor tissues were collected.  
Their tumor DNA was sequenced to determine the genomic locations into which 
transposons had inserted.  This resulted in an average of 124 insertions site mutations in 
each tumor (Starr et al., 2009).  The sites of these insertions were analyzed to determine 
which genes had more insertions than expected by chance.  Genes that had more 
insertions than expected by chance are called common insertion sites.  Since these genes 
had more insertions than expected by chance, the insertion must likely provide a selective 
advantage to the tumor.  Therefore, these genes are considered candidate cancer-causing 
genes.  77 candidate cancer-causing genes were identified.  At the top of this list was 
Apc, and also in the top 10 was a new candidate gene, Kcnq1. Examination of the 
literature revealed that the best understood role of KCNQ1 in the intestine was to provide 
the electrical driving force for export of chloride ions by CFTR.  Cftr was also a CIS gene 
in the list of 77 identified as candidate cancer-causing genes 
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 To further explore the role of Kcnq1 in colorectal cancer, Kcnq1 was knocked out 
via a targeted deletion mutation in ApcMin mice (Than et al., 2014).  The ApcMin Kcnq1 
KO mice developed a 2-fold increase in gastrointestinal tumors compared to the ApcMin 
Kcnq1 WT mice, suggesting that Kcnq1 has a role as a tumor suppressor (Than et al., 
2014).  The Kcnq1 KO mice also showed changes in their intestinal global gene 
expression, suggesting that the Kcnq1 pathway plays a major role in the intestine (Than et 
al., 2014).  The changes in gene expression in the Kcnq1-deficient intestine were 
examined and was found to overlap with changes in gene expression in Muc2-deficient 
and Cftr-deficient intestine.  This result suggests that Muc2 and Cftr could be involved in 
the same pathway as Kcnq1, perhaps in a similar tumor suppressive role.     
To examine the effect of Kcnq1 on the stem cell compartment, organoids were 
developed from the intestinal crypts of the Kcnq1 KO and WT mice.  The Kcnq1 KO 
organoids demonstrated a much higher clonogenicity, or ability to produce more 
Figure 7: A) Cumulative overall survival for stage IV colorectal cancer patients with 
either high (green) or low (blue) expression of KCNQ1.  High expression of KCNQ1 
results in extended survival by 23 months. B) The number of patients surviving at 
each time point, for both KCNQ1 low and high expression. Than et al., 2014.  
A 
B 
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organoids.  As clonogenicity may be determined by the stem cells “stemness”, this 
suggests a regulatory role of Kcnq1 within the intestinal stem cell (Than et al., 2014). 
To determine whether the observation of Kcnq1 deficiency driving tumorigenesis 
in mice was true in humans, KCNQ1 expression was studied within human tumor 
samples collected from 500 stage IV colorectal cancer patients with liver metastases 
(Than et al., 2014).  These patients all had hemihepatectomy, the removal of one or more 
lobes of the liver (Than et al., 2014).  Of the 500 patients, KCNQ1 expression was 
examined in 311 of those patients, and it was found that higher expression of KCNQ1 
correlated with better median survival for these patients by a highly significant 23 months 
(Figure 7; Than et al., 2014).  Therefore, it was concluded that KCNQ1 is a tumor 
suppressor in human colorectal cancer.   
 
KCNQ1 
 KCNQ1, potassium voltage-gated channel subfamily Q member 1, is located on 
chromosome 11p15.5, encoding a voltage-gated potassium channel.   This channel allows 
Figure 8: Role of KCNQ1 in cell. KCNQ1 channel, located on 
basolateral membrane, allows movement of intracellular 
potassium out of the cell. Alzamora et al., 2011.   
 
KCNQ1 
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the movement of potassium out of the cell (Figure 8; Alzamora et al., 2011).  The 
channel is located on the plasma membrane of the cell, and is expressed in various 
locations throughout the body, including the heart, kidney, inner ear, and the 
gastrointestinal tract (Abbott, 2014).  In the intestine, KCNQ1 is expressed within the 
intestinal crypt, in the stem cell compartment (Alwan unpublished; Preston et al., 2010;  
Jadhav et al., 2017; Schroeder et al., 2000).  KCNQ1 maintains water and ion 
homeostasis within the epithelial tissue cells (Warth et al., 2002).  In mice with KCNQ1 
KO, the cellular ionic balance was disrupted.  A lack of functional potassium channels 
prevented the movement of potassium into the basolateral extracellular space.  Due to this 
altered ionic gradient, chloride ions were prevented from moving into the apical 
extracellular space also (Warth et al., 2002).   
 Alteration and mutations in KCNQ1 are linked to many other disorders besides 
colorectal cancer.  Mutations in KCNQ1 have been seen in long QT syndrome, a 
condition of the heart wherein repolarization of the ventricular tissue is elongated.  This 
condition can cause cardiac arrhythmias, which can cause death (Crotti et al., 2008).  
Mutations in KCNQ1 are also associated with Jervell and Lange-Nielson syndrome, a 
rare disorder that causes deafness as well as long QT syndrome (Than et al., 2014; (Vyas 
et al., 2016).  Moreover, KCNQ1 mutations have been indicated as a susceptibility gene 
for Type 2 diabetes (Kasuga, 2011).  KCNQ1 mutations also play a role in epilepsy 
development, often in conjuncture with long QT syndrome (Villa & Combi, 2016).     
 Although the regulation of KCNQ1 is not completely understood, two factors are 
thought to play a role, KCNQ1OT1 and β-catenin.  KCNQ1OT1 is a long non-coding 
RNA which is encoded within intron 10 of KCNQ1.  β-catenin is a protein usually found 
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near the cell membrane and in the cytoplasm but when localized to the nucleus acts as a 
transcription factor to induce proliferation (Zhan et al., 2017).  Both these factors are 
thought to regulate KCNQ1, but their particular roles are very complicated.  
 KCNQ1OT1 is an imprinted gene that encodes an antiparallel long non-coding 
RNA which regulates in cis the other genes in its domain.  An imprinted gene is 
monoallelically expressed due to a developmental epigenetic silencing of one allele. 
(Chiesa et al., 2012).  KCNQ1OT1 contains a promoter CpG island that when methylated 
results in silencing of transcription. KCNQ1OT1 is normally methylated on the maternal 
gene and expressed only on the paternal gene (Figure 9; Chiesa et al., 2012).   (Kanduri, 
2016).  Methylation is regulated and maintained through the activity of enzymes called 
DNA methyltransferases, or DNMTs (Scott et al., 2014).  This methylation patterning is 
extremely important to control gene expression levels in the various stages of 
development (Kanduri 2016).    
 When mutations and alterations occur that cause changes in the methylation 
pattern of KCNQ1OT1, many problems can occur.  If KCNQ1OT1 is hypomethylated, 
Figure 9:  Imprinting paternal of KCNQ1OT1. KCNQ1OT1is 
methylated on the maternal alleles, and only expressed on the 
paternal allele (Weksberg 2002). White genes are expressed, 
black genes are not expressed 
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both alleles of KCNQ1OT1 are expressed. This can lead to Beckwith-Wiedemann 
syndrome (Weksberg et al., 2003).   Beckwith-Wiedemann syndrome is a complicated 
disease which can result in infant overgrowth, failure of the abdominal wall to develop 
properly, and an increased risk for tumor development (H’mida Ben-Brahim et al., 2015).  
Even if KCNQ1OT1 is partially hypomethylated, it can lead to a mosaic of differential 
expression of KCNQ1OT1 throughout tissues (H’mida Ben-Brahim et al., 2015).  
Another common disease associated with aberrant methylation of KCNQ1OT1 is Silver-
Russell syndrome (Eggermann, Eggermann, & Schönherr, 2008).   This syndrome results 
in growth retardation and KCNQ1OT1 is often hypermethylated, resulting in decreased 
KCNQ1OT1 expression (Eggermann, Eggermann, & Schönherr, 2008).  Therefore, there 
is a very delicate balance of gene expression conferred by this imprinting by methylation.  
If disturbed, it can have very serious outcomes for the individuals involved.   
KCNQ1OT1 acts as a regulator to the genes in its domain (Pandey et al., 2008).  
The full length of KCNQ1OT1 must be expressed for regulation of the genes within its 
domain or the imprinted control region (ICR) (Mancini-DiNardo, Steele, Levorse, 
Ingram, & Tilghman, 2006).  KCNQ1OT1 interacts with the DNA as well as with the 
histone methyltransferases H3K9 and H3K27, resulting in regulatory chromatin 
rearrangements (Pandey et al., 2008; Jones, Bogutz, & Lefebvre, 2011; Kanduri 2011).  
KCNQ1OT1 also is thought to interact with Dnmt1, a DNA methyltransferase, to regulate 
the gene silencing (Mohammad, Mondal, Guseva, Pandey, & Kanduri, 2010).  KCNQ1 
and other genes are expressed within the KCNQ1OT1 domain (Korostowski et al., 2012).  
KCNQ1OT1 is thought to inhibit expression of the genes of this domain.  
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However, there has been mixed data whether or not KCNQ1 is also regulated by 
KCNQ1OT1 (Pandey et al.,  2008).  KCNQ1 has been reported to be regulated by 
KCNQ1OT1 expression in blood leukocytes (Valente et al., 2019).   On the other hand, it 
has been reported in mouse heart tissue that although KCNQ1OT1 down regulates the 
expression of other genes in the domain, the expression of KCNQ1 is independent to the 
imprinting of KCNQ1OT1 (Korostowski et al., 2012.  These data suggest that there is 
more regulation occurring within this gene domain than just the activity of KCNQ1OT1.  
One possibility is the presence of enhancers within the KCNQ1OT1 ICR (Schultz et al., 
2015).  These enhancers may counteract the activity of downregulation by KCNQ1OT1, 
allowing expression of the genes within this imprinted region (Schultz et al., 2015).   
The other major candidate for regulation of KCNQ1 is the transcription factor β-
catenin.  β-catenin is the major component of the Wnt/ β-catenin pathway which plays 
such a pivotal role in colorectal cancer.  We would expect to see a negative correlation 
between KCNQ1 and β-catenin, as β-catenin is a pro-cancer transcription factor, and  
KCNQ1 is a tumor suppressor. However, there are contradicting results in the literature.  
In colorectal cancer cell lines, KCNQ1 and β-catenin interact bidirectionally.  When 
KCNQ1 expression is decreased, β-catenin moves from the membrane into the cytoplasm, 
when KCNQ1 is increased, β-catenin moves from the cytoplasm back into the membrane, 
and β-catenin in the nucleus leads to decreased KCNQ1 expression (Rapetti-Mauss et al., 
2017).   
 There are several papers that suggest a positive correlation between KCNQ1 and 
β-catenin expression.  In oocytes, increased β-catenin expression in the plasma membrane 
has been correlated with increased KCNQ1 expression in the cytoplasm and plasma 
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membrane (Wilmes et al., 2012).  In human colorectal cancer protein data, nuclear β-
catenin was correlated to increased KCNQ1 protein expression (den Uil et al., 2016).  β-
catenin in the nucleus has also been shown to increase the expression of KCNQ1 via 
increased activity of SGK1-a serine/threonine protein kinase (Strutz-Seebohm et al., 
2009).  Therefore, there is much conflicting evidence as to the relationship between 
KCNQ1 and β-catenin (Figure 10).  There is yet another layer of complexity in the 
interactions between β-catenin and KCNQ1, as β-catenin itself is thought to regulate 
KCNQ1OT1 expression (Sunamura et al., 2016).   
Identification of Tumor Suppressor CFTR 
 As described above, Cftr was identified as a CIS gene in the same screen as 
Kcnq1.  KCNQ1 export of potassium ions provides the electrical driving force for the 
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export of chloride ions by CFTR.  Therefore, CFTR was postulated to play an important 
role in colorectal cancer also.  
To test whether Cftr may also be a tumor suppressor, ApcMin mice were crossed 
with Cftr Fl/Fl Villin-Cre mice to produce a conditional KO of Cftr in the intestinal tract  
(Than et al., 2016).  In Apc+/+ Cftr Fl/Fl Villin-Cre mice, Cftr defiency alone was 
sufficient to cause intestinal adenoma tumors in 60% of the population after one year 
(Than et al., 2016).  Organoids were produced from these Cftr deficient mice, and 
clonogenicity was increased significantly when compared to Cftr WT organoids (Than et 
al., 2016).  CFTR was also examined in human tissue mRNA samples from stage II 
colorectal cancer patients (Than et al., 2016).  Within this cohort, CFTR expression was 
correlated with increased survival rates, solidifying CFTR’s role as a tumor suppressor in 
colorectal cancers (Than 2016). 
 
CFTR, Cystic Fibrosis, and Colorectal Cancer  
 CFTR, cystic fibrosis transmembrane conductance regulator, is located on 
chromosome 7q31.2, and encodes a protein which forms a chloride channel in cells 
responsible for the production mucus, tears, and sweat (NIH, 2019).  This chloride 
channel is extremely important for the regulation of these various fluids (Kleme et al., 
2016).  CFTR is expressed in the respiratory tract and the intestine.  Similar to KCNQ1, 
CFTR is expressed within the intestinal crypt.  CFTR is expressed in the respiratory tract, 
gastrointestinal tract, pancreas, gull bladder, and the spleen (NCBI, 2019).    
Cystic fibrosis is a very deadly genetic disease, leading to airway blockages due 
to mucus build-up (Quinton, 1983).  It is the most common autosomal recessive disease 
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in Caucasians.  Of all genetic diseases, cystic fibrosis is responsible for the most deaths 
among Caucasian populations (Kleme et al., 2016) .  In 90% of patients, lung disease, 
often brought on by infections is the ultimate cause of death (Burney & Davies, 2012).  It 
was identified in 1938 by Dorothy Anderson after a heat wave in New York resulted in 
peculiar cases of lung infection along with extreme salt loss through the sweat (Elborn, 
2016).  The cause of this disease, improper ion transport due to a mutated CFTR protein, 
was not determined until nearly a half century later (Kerem et al., 1989).  Cystic fibrosis 
is inherited in an autosomal recessive manner, primarily affecting the respiratory system 
and gastrointestinal tissues (Fuchs et al., 1994).  Patients with cystic fibrosis develop 
serious mucus accumulation and inflammation within their lungs and airways (Elborn, 
2016).  When CFTR is functioning, it allows the movement of chloride into the airway 
space.  Water follows to maintain the ion gradient, and this keeps the mucus layer thin 
(Rafeeq & Murad, 2017).  However, when CFTR is not functioning, chloride ions do not 
move out of the cells, and thus the water does not move into the mucus layer, and the 
mucus becomes thick and immobile (Rafeeq & Murad, 2017).  This abnormal mucus 
layer provides a highly favorable environment for the growth of bacteria, resulting in 
serious lung infections (Rafeeq & Murad, 2017).  This environment leads to 
bronchiectasis, a thickening of the bronchi due to inflammation and infection (Elborn, 
2016).  There are other organs affected by mutations in cystic fibrosis, including 
gastrointestinal blockages, pancreatic dysfunction, and an ionic imbalance due to excess 
salt released in the sweat (Rafeeq & Murad, 2017).  
Cystic fibrosis patients can have various mutations within the CFTR gene, which 
results in a lack of a mature protein in the membrane (Cheng et al., 1990).  There are 
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more than 2000 gene mutations that have been observed in CFTR which can lead to the 
development of cystic fibrosis (Elborn, 2016).  These mutations have been organized into 
different classes, determined by what functional effect the mutation has on the CFTR 
protein (Elborn, 2016; Burney & Davies, 2012).  One mutation, F508del (deletion of the 
508th amino acid, phenylalanine), is present in 70% of all cystic fibrosis cases (Rafeeq & 
Murad, 2017).   
Cystic fibrosis patients have an increased risk for colorectal cancer, nearly 5-10 
times greater than someone who does not have cystic fibrosis (H’mida Ben-Brahim et al., 
2015; Yamada et al., 2018; Maisonneuve et al., 2013).  That risk increases for these 
patients up to 25-30 times a greater risk after an organ transplantation (H’mida Ben-
Brahim et al.,2015).  To better understand how to treat both cystic fibrosis and colorectal 
cancer, more must be understood about the regulation of CFTR, and its role in the 
intestine.   
Specifically, we wanted to examine how CFTR may be interacting with the major 
drivers of colorectal cancer in the intestinal crypt.  Since β-catenin is the most important 
pathway in the intestinal crypt environment, we chose to investigate the interactions of 
CFTR and β-catenin.  As with KCNQ1, we would expect a negative correlation between 
CFTR and β-catenin, as β-catenin is a pro-cancer transcription factor and CFTR is a 
tumor suppressor.  
Several groups have reported that CFTR deficiency leads to increased β-catenin 
activity in the nucleus (Than et al., 2016; Strubberg et al., 2018; Zhang et al., 2018).  
This has been reported in murine adenomas and organoid cultures.  However, CFTR 
defiency has also been reported to cause decreased nuclear β-catenin in whole intestinal 
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lysates (Liu et al., 2016).  It has been suggested by Strubberg et al., that the difference 
may be due to an alteration in CFTR activity in the stem cell compartment compared to 
the whole intestine.  However, more information is needed to understand CFTR and β-
catenin’s interactions with each other in the intestinal stem cell compartment.   
Gaps in Knowledge 
 In colorectal cancer, KCNQ1 and CFTR have been established as tumor 
suppressors, and the low expression levels of these tumor suppressors are indicators of 
poor prognosis colorectal colon cancers (Liu et al., 2014; Than et al., 2016; den Uil et al., 
2016).  However, the question of how these tumor suppressors are regulated and their 
underlying mechanism of action remains a major gap in knowledge. Specifically, their 
relationship with β-catenin must be investigated.  The Wnt/ β-catenin pathway is the most 
important pathway within the intestinal crypt, as it regulates the crypt environment, 
determines proliferation rate, and regulates stemness.  The relationship between KCNQ1 
and β-catenin, and between CFTR and β-catenin is still a convoluted story which needs 
clarification.   
Understanding their activity within the colon stem cell compartment is also of 
vital importance, as the stem cell compartment is thought to be the site of initiation for 
colorectal cancer.  The majority of data collected in non-cancer models has been done 
with small intestine.  Although small intestine models are a valuable tool for 
understanding how the crypts and stem cells function, more information is needed to 
understand the dynamics of the colon intestinal crypts, and whether they differ 
significantly from the small intestinal environment.  This area is a significant gap in 
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knowledge and more intestinal stem cell work needs to be conducted within colon stem 
cell models.     
 
Hypotheses 
My thesis will address several of these gaps in knowledge.  I will first investigate 
whether β-catenin regulates the expression of KCNQ1.  I hypothesize that β-catenin down 
regulates the expression KCNQ1.  Higher β-catenin expression, during APC loss, is 
associated with development of colorectal cancer.  Therefore, we would expect that 
KCNQ1 would be down regulated when β-catenin was high.  I will investigate this 
hypothesis using siRNA experiments, luciferase reporter assays and RT-qPCR.  
I will also address the mechanism for KCNQ1 and CFTR as tumor suppressors in 
a stem cell model: colon organoids.  The organoids will be harvested from murine colon 
intestinal crypts, providing valuable information regarding the interactions within the 
colon stem cell compartment.  I hypothesize that KCNQ1 and CFTR may be regulating β-
catenin activity within the intestinal stem cell compartment.  If so, it may suggest that 
KCNQ1 and CFTR act as tumor suppressors through their regulation of β-catenin.  I will 
investigate this hypothesis through immunofluorescent staining of β-catenin in colon 
stem cell organoids.   
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Chapter 1: Regulation of KCNQ1 by KCNQ1OT1 and β-catenin 
 
Materials and Methods 
 
Cell Culture   
 
 Colorectal cancer cell lines were obtained from American Type Culture 
Collection (ATCC).  Two cell lines were utilized: T84 and SW480, both adherent.  T84 is 
a colorectal carcinoma cell line, derived from a lung metastasis from a 72 year old male.  
SW480 is a colorectal adenocarcinoma cell line, derived from a Duke’s type B tumor 
harvested from a 50-year old male patient.  Both cell lines were cultured at 37°C in 5% 
CO2 in DMEM (Dulbecco’s modified Eagle’s medium), with 10% FBS and 1% 
Glutamine.  The cells were fed or passaged every three to five days.   
 For feeding, the existing media was removed from the cell culture flasks, and 4ml 
of fresh media was added to the cells.  For passaging, the old media was removed from 
the flask, and 2ml of phosphate buffered saline (PBS) was added to rinse the remaining 
media from the flask.  The cells were treated with Trypsin-EDTA (ethylenediamine 
tetraacetic acid) and incubated for two to three minutes at 37°C in 5% CO2.  After 
trypsinization, 4ml of media was added back to the flask, to neutralize the trypsin 
reaction.  The cells were moved to a 15ml conical tube and centrifuged at 300xg for 3 
minutes.  The cells, now in a pellet at the bottom of the conical tube, had the 4ml of 
media removed from above the pellet using a glass Pasteur pipette connected to a vacuum 
system.  The pellet was resuspended in 2ml of media, and a select dilution was added to 
4ml of fresh media in a fresh cell culture flask.  The cells were returned to the incubator 
37°C at 5% CO2.   
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RNA Harvest for RT- qPCR  
 T84 and SW480 cells were plated at 7x105 cells/dish and incubated for 24 hours 
at 37°C at 5% CO2.  The cells were harvested for total RNA using the QIAGEN RNeasy 
Mini Kit (Cat # 74104).  The cells were first collected from the cell culture dishes by 
trypsinization, then resuspended in 1ml of media in a 1.5ml Eppendorf tube, and put on 
ice.  The cells were spun down in a micro centrifuge for 5 minutes at 1,200 rpm at 4°C.  
All media was removed from the cells, now in a pellet at the bottom of the tube.  600µl of 
RLT buffer was added to the cell pellet to disrupt the cells, and the solution was pipetted 
gently until the pellet was resuspended.  The cells were homogenized 15 times with a 1ml 
255/8G syringe.  To precipitate the RNA, one volume of 100% ethanol was added to the 
sample which was mixed by pipetting.  The solution was transferred to a column, and the 
liquid was drawn through the membrane by centrifugation.  The flow through was 
discarded.  The column was treated with a DNase solution to remove DNA in the 
column.  The RNA column was washed with an ethanol buffer, RPE, and spun empty to 
remove residual ethanol.  DNase/RNase free water was added to elute the RNA and 
measured on a Nanodrop to determine concentration.    
  
siRNA Knockdown of KCNQ1OT1 and β-catenin in SW480 cells 
SW480 cells were grown at a concentration of 2x105 cells/dish and incubated for 
48 hours at 37°C, 5% CO2.  The cells were transfected with 75ng of a combined solution 
of four KCNQ1OT1 siRNAs (Cat# S105393696, S104713625, S104713618, 
S1036663240), or β-catenin siRNAs (Cat.# S1002662478).  A siRNA control, OT3, was 
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used in all experiments.  OT3 is a negative siRNA control: an siRNA without a target 
sequence.  This control is necessary to determine that our effect is due to the specific 
gene being targeted, and not the presence of the siRNA alone.  The cells were incubated 
at 37°C, 5% CO2 for 24 hours, after which the cells were collected for RNA harvest.    
 
Reporter Assay Cell Culture 
 The cell line HEK293 was obtained from American Type Culture Collection 
(ATCC).  HEK293 is an epithelia human cell line isolated from an embryonic kidney. 
This cell line was kept at 37°C and 5% CO2 in DMEM (Dulbecco’s modified Eagle’s 
medium), with 10% FBS and 1% Glutamine.  The cells were fed or passaged every three 
to five days.   
 
Molecular Cloning 
 The cloning plasmid pLS-LR was provided by Dr. Matthew Slattery (Figure 15).  
This plasmid contains an ampicillin resistance gene, a restriction digest site capable of 
allowing cleaving by Kpn1, Sac1, Mlu1, Nhel, Xho1, BgLII, and HindIII. This region is 
followed by a TK basal promoter, followed by a Renilla SP optimized luciferase gene.     
 Our inserts of interest were obtained from Integrated DNA Technologies (IDT) 
with specific restriction digest sites on either end.  The cloning plasmid was digested 
BgLII and MluI to create the correct sticky ends for cloning.  The restriction digest was 
tested on a gel to assure that the plasmid was successfully cleaved.   
Depending on their size, IDT prepared the inserts as double stranded, or single 
stranded.  For cloning, double stranded inserts are necessary.  This required the annealing 
of the single stranded inserts to their complementary base pair matching strand.  To 
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anneal, the single stranded inserts were diluted to 100 pmol/µl.  1 volume of Tris-EDTA 
(TE) buffer was added to the inserts and diluted down to 20pmol/µl in TE buffer.  2.5µl 
of each insert solution (forward and reverse strands) were added to 5µl of 10X STE 
buffer, and 40µl of water.  The tube was placed in a 95°C heat block for 3 minutes.  The 
heat block was unplugged, and the tube slowly cooled to room temperature (RT) 
overnight.  The annealed sample was put at -20°C.   
The inserts were ligated into the cloning plasmid pLS-LR (Figure 9).  A carefully 
measured ratio of vector: insert was prepared depending on size of insert.  This ratio was 
determined by use of the New England Biolaboratories ligation calculator.  This reaction 
also contained ligase buffer, T4 DNA ligase, and H20.  The sample incubated for 30 
minutes at RT, and frozen at -20°C.   
The plasmids, hopefully with inserts present, were transformed into DH5-alpha 
Escherichia coli (E. coli).  Colonies were selected and placed in LB (Luria-Bertani) 
broth, with ampicillin (1:1000).  After sixteen hours at 37°C with shaking, allowing for 
proliferation of the transformed bacteria, the plasmid DNA was isolated with a Qiagen 
miniprep procedure.  To determine whether our insert was present in the plasmid, the 
DNA was treated with the same restriction enzymes as were used in the initial cloning 
and run on a gel to determine whether the inserts were present in the samples.  RT-qPCR 
was used to amplify the smaller segments to allow gel visualization.  
 
Luciferase Reporter Assay 
 HEK293 cells were growth in DMEM media in white 96 well plates at a seeding 
density of 2,000 cells/ well and incubated at 37°C, 5% CO2 for 24 hours.  The next day 
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the cell’s media was changed to OptiMEM media, transfected with the 75ng of the cloned 
pLS-LR plasmid, incubate for 24 hours (Figure 11).  A control plasmid was also 
transfected into separate wells for normalization.  The next day the media was changed to 
Wnt media or DMEM media, and the cells were again incubated at 37°C and 5% CO2 for 
24 hours.  The next day the plate was wrapped in parafilm and frozen at -80°C for 24 
hours to induce lysis of cells.  The next day, the assay plate was removed from the -80°C 
freezer half an hour before the start of the luciferase assay.  After the allotted 30 minutes, 
100X substrate solution diluted 1:1000 in assay buffer was added to the plate, after which 
the plate was immediately wrapped in tin foil and incubated at RT for another 30 
minutes.  The plate was read in a luminometer plate reader.  
 
 
 
Figure 11: General method for luciferase assay. Sequences cloned into our reporter 
plasmid.  Plasmids are then transfected into cells, wherein the luciferase gene is 
expressed, Luciferin protein is made, and the resulting light signal is read on a 
luminometer. SwitchGear Genomics 2017.  
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Results 
I. Regulation of KCNQ1 by KCNQ1OT1 
Comparison of  cells lines with altered KCNQ1OT1 methylation patterns 
 KCNQ1OT1 expression is downregulated by promoter CpG island methylation.  
To determine if KCNQ1 was regulated by KCNQ1OT1 we compared expression in two 
colorectal cancer cell lines known to be differently methylated: T84 has one 
unmethylated allele, and SW480 has both alleles are unmethylated (Nakano et al., 2006).  
Based on our understanding of regulatory relationship of KCNQ1OT1 on KCNQ1, we 
expected KCNQ1 levels to be higher in T84 cells than in the SW480 cells.  However, we 
saw the opposite effect in the KCNQ1 expression, and there was no difference between 
the mRNA expression of KCNQ1OT1 in the two cell lines (Figure 12).  This result 
suggests that factors other than promoter methylation affect KCNQ1OT1 expression and 
factors other than KCNQ1OT1 affect KCNQ1 expression in these cell lines. 
This could suggest that KCNQ1OT1 expression does not change significantly 
when there is one allele unmethylated compared to when two alleles are        
Figure 12: Expression of KCNQ1OT1 and KCNQ1, normalized to 18S. One biological replicate. 
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unmethylated.  This suggests that these cell lines are not a good model for examining 
these gene interactions.  It could also suggest that KCNQ1 expression is not dependent on 
KCNQ1OT1 alone.   
 
siRNA KD of KCNQ1OT1 
 To examine this interaction in another way, we attempted to knockdown the 
expression of KCNQ1OT1 using siRNA.  We hoped this would demonstrate how the 
removal of KCNQ1OT1 expression affected the expression of KCNQ1.  SW480 cells 
were transfected with a mixture of four KCNQ1OT1 siRNAs, and RNA was harvested.  
We used a non-targeting siRNA, OT3, as a negative control.  However, the siRNA 
knockdown of KCNQ1OT1 was unsuccessful (Figure 13).  siRNAs act primarily in the 
cytoplasm, while KCNQ1OT1 has been reported to localize to the nucleus (Pandey et al., 
2008).  This is probably the reason that the KD of KCNQ1OT1 was unsuccessful.  
Figure 13: siRNA knockdown (KD) of KCNQ1OT1 in SW480 cells. OT3 is a non-
targeting siRNA control.    
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KD of β-catenin expression via transfection of siRNA 
 To explain the interaction between KCNQ1 and KCNQ1OT1 more effectively, 
we next decided to knockdown expression of β-catenin in the SW480 cells.  β-catenin 
directly regulates the expression of KCNQ1OT1.  When β-catenin expression is low, 
KCNQ1OT1 expression is also low (Sunamura et al., 2016).  We did an siRNA 
knockdown of β-catenin in SW480 cells and examined the expression of β-catenin, 
KCNQ1, and KCNQ1OT1 mRNAs using RT-qPCR (Figure 14).  The expression of β-
catenin was decreased in the β-catenin depleted samples, as was the expression of OT1 as 
reported in the literature (Sunamura et al., 2016).  However, the expression of KCNQ1 
was also decreased slightly.  This result suggests that either neither KCNQ1OT1 or β-
catenin affects KCNQ1 expression, or possibly that they have opposing effects.  The 
Figure 14: siRNA KD of β-catenin.  All gene expression is normalized to 18S. 
One replicate in SW480 cells.  
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depletion of β-catenin down regulates and decreases KCNQ1OT1, while also decreasing 
the expression of KCNQ1. 
 
II. KCNQ1 genomic enhancer region  
Identification of putative enhancer  
 To examine KCNQ1 expression using another approach, the KCNQ1 genomic 
sequence was surveyed for eQTLs (SNPs, or single nucleotide polymorphisms) 
associated with altered expression of KCNQ1).  This analysis, conducted by Dr. Matthew 
Slattery, identified SNP rs2283155 in KCNQ1 intron 2 that was associated with 
differential KCNQ1 expression.  This SNP was located within a putative enhancer region 
characterized by DNase hypersensitivity.  This SNP could represent a regulatory site 
itself or more likely, it could be in linkage disequilibrium with another variant that alters 
KCNQ1 expression (Figure 15; Dr. Slattery, unpublished).  We tested the hypothesis that 
this region regulates KCNQ1 expression.   
 
Figure 15: KCNQ1 expression in individuals separated by genotype at the ICR 
enhancer SNP. The C allele is associated with low KCNQ1 expression and the T allele 
is associated with high expression. Data are based on the thyroid gene expression data 
from the GTex project (Dr. Slattery, unpublished) 
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Development of reporter assay  
 Therefore, to determine whether this putative enhancer region, marked by SNP 
rs283155 was an active enhancer region within our system, I cloned specific regions of 
the putative enhancer region (Figure 16) into a reporter plasmid (Figure 17).  The reporter 
plasmid is an established model for determining activity of putative enhancer regions.  
The reporter plasmid contains restriction enzyme cleaving sites followed by a basal 
promoter, a luciferase gene, the site of origin, and an ampicillin resistance gene.  The 
basal promoter will induce expression of the luciferase gene slightly, low levels of 
luciferase protein will be made, and there will be a low luciferase signal when        
Figure 16: Putative enhancer region within KCNQ1 intron 2. A) UCSC genome browser 
readout of KCNQ1 region and location of SNP. Red box shows general location of 
enhancer region. B) Map of enhancer region. Red is KCNQ1 gene. Yellow indicates the 
DNaseI hypersensitivity region (a region that is allows greater access by DNase I, 
indicating an increased accessibility of the chromatin). Blue is the SNP. Green is 
TCF7L2, the binding site for TCF, a binding partner for β-catenin. TE is the end of the 
DNase sequence. C) The three sequences that I cloned to test for regulatory activity. 
UCSC Genebank.  
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luciferin is added to the cells.  If the insert is an enhancer, the luciferase signal will 
increase, and if the insert is a down regulator, the luciferase signa will decrease.  Since 
this putative enhancer contains a TCF7L2 binding site, and TCF7L2 is the DNA binding 
partner for transcriptionally active β-catenin, we decided to examine whether the putative 
enhancer was active in the Wnt/ β-catenin pathway.  We tested this by treating our cells 
with Wnt, to induce β-catenin activity. 
There were several layers of troubleshooting before we got reliable results with 
the reporter assay.  I first tested two different control plasmids: LDHA and NQO1.  LDHA 
is a housekeeping gene encoding a lactate dehydrogenase with moderate to low 
expression in cells (Tagliafierro et al., 2016).  NQO1 is a gene encoding NADPH 
quinone dehydrogenase which is highly expressed in cells Gray et al., 2016).  I therefore 
Figure 17: Reporter plasmid pLS-LR. The plasmid contains a basal 
promoter, and a restriction digest-surrounded region for cloning of 
the sequence of interest. The luciferase gene, RenSP, allows for 
detection of enhancer/ regulator activity by the inserted sequence. 
The plasmid also contains an ampicillin resistance gene, to provide 
a method by which to select it during the transformation steps. 
SwitchGear Genomics. 
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expected to see the LDHA control vector yield lower luciferase expression when 
compared to the NQO1 vector.  The first attempt of the luciferase assay I included only 
the LDHA vector in Hct116 cells, a colorectal cancer cell line.  This resulted in in 
extremely low luciferase expression (Figure 18).   
Figure 19: Reporter luciferase assay: NQO1 and LDHA, Hct116. 
Each number is an individual well.  
Figure 18: Reporter luciferase assay: LDHA control vector 
luciferase expression in Hct116.  Values are averages of ten 
wells each.  
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Since LDHA gene expression is known to be low in cells, I also tried NQO1, 
which is known to have higher expression to determine if my low expression of LDHA 
alone was simply due to a constitutively low expression of our cells.  NQO1 did have 
much higher expression, however, the expression levels were not consistent (Figure 19).   
I then began to test my own cloned plasmids, beginning with the TCF7L2 
sequence and the TDHS sequences (Figure 16), treated with Wnt and without Wnt.  I 
used the LDHA and NQO1 plasmids as controls.  The Wnt-treated samples had extremely 
low expression compared to the others (Figure 20).  I concluded that the Wnt media was 
interfering with some aspect of the luciferase assay. 
 Therefore, I set up an experiment with either Wnt-containing media or OptiMEM 
media at each stage of the assay (Figure 21).  After doing this, it appeared that the Wnt 
media did interfere with the transfection but did not affect the growth phase or the actual 
 
Figure 20: Reporter luciferase assay: TCF7L2 construct compared to TDHS 
construct with C version of SNP. LDHA was used as a control 
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luciferase assay itself (Figure 21).  Therefore, I decided to do my transfections in 
OptiMEM media and change it to Wnt-containing media 24 hours after the transfection.  
Despite transfecting my cells in OptiMEM media instead of Wnt containing 
media, my following luciferase assays still were not giving me as high yields as I would 
have expected.  I added the optional freezing step which is necessary to lyse all the cells 
in the wells.  Although the luciferase solution in a lysis buffer, freezing makes the lysis 
step much more effective.  Lysis of the cells is necessary to allow to be detected by the 
luminometer.  After I began freezing the plates, I was seeing better luciferase expression 
(Figure 22).   
Figure 21: Reporter luciferase assay: Wnt experiment to 
determine which stage the Wnt media was interfering with.  
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However, I wanted to achieve the highest possible luciferase expression to get 
trustworthy results.  I compared the expression levels of the luciferase assay in HEK293 
vs. Hct116 cells.  The HEK293 yielded much higher expression values (Figure 23).  
colorectal cancer cell line; they are an embryonic kidney cell line.  However, they       
Figure 22: Reporter luciferase assay: Luciferase expression after freezing plate, 
with TCF7L2 construct and the TDHS construct with C version of SNP. LDHA 
plasmid is the control. Each was treated with Wnt or no Wnt media  
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Figure 23: Reporter luciferase assay: Luciferase expression of HEK293 
cells and Hct116 cells.  
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have high efficiency for transfections and an active Wnt/ β-catenin pathway (Kim et al., 
2008).  Therefore, to effectively determine whether our putative enhancer sequence was 
an active regulator, I decided to continue the rest of my assays with the HEK293 cells.  
 
Evaluation of putative enhancer region  
 
Now that the assay was giving reliable results, I began to examine all my cloned 
sequences.  The first I tried was the TCF7L2 binding site and some surrounding DNA, a 
construct of 65 bp.  This sequence included only the TCF7L2 binding site, as well as a 
small amount of surrounding DNA (Figure 16).  I expected this site to be increased in 
response to Wnt treatment, as Wnt activates the activity of β-catenin in the nucleus, and 
therefore, should induce binding of β-catenin at the site of interest, leading to increased 
expression of our reporter gene.  With Wnt treatment, I expected and observed increased 
luciferase expression in the presence of Wnt (Figure 24).   
The next sequence I cloned, TDHS, included the entire DNase hypersensitive 
region as well as the SNP and the TCF7L2 binding site (Figure 16).  I made two separate 
constructs to test both versions of the SNP.  I expected to see a difference in expression 
of luciferase if this region of DNA is acting as an enhancer or a down regulator of gene 
expression (Figure 23).  The TDHS sequences yielded interesting results.  The luciferase 
expression was increased with Wnt, but less than the TCF7L2 binding site alone. There 
was no differential expression between two different versions of the SNP. 
I also cloned a third sequence, TE, which includes the end of the DNase sensitive 
region, without either the SNP or the TCF7L2 binding site (Figure 16).  This sequence 
was cloned to check for the regulator activity at the end of the TDHS sequence, and this 
sequence has no detectable regulatory activity (Figure 24). 
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Our enhancer region appears to be an active regulator.  Interestingly, in the presence of 
our enhancer, the reporter gene has a smaller increase in expression compared to the 
TCF7L2 binding site alone.  This suggests that our enhancer may have an inhibitory 
effect.  
Evaluation of enhancer target by RT-qPCR 
 We next wanted to determine which gene is being regulated by this enhancer 
region.  We hypothesized that this enhancer region was regulating either KCNQ1 or 
KCNQ1OT1 due to its location within the second intron of KCNQ1.  To test this, I treated 
HEK293 cells with and without Wnt to replicate the conditions of the reporter assay.  I 
harvested the RNA for RT-qPCR to measure the KCNQ1 and KCNQ1OT1 mRNA 
Figure 24: Reporter luciferase assays, with the three sequences of interest molecularly cloned into 
the pLS-LR vector.  Each sample has been treated with Wnt, and a no Wnt control. The values 
have been normalized to a housekeeping vector, RPL, and then divided by the no Wnt control to 
determine the ratio between the two. P values were obtained from a 2-tail T-test. Error bars are 
standard deviation. Two replicates were done for TCF7L2, 3 for each TDHS, and 1 for TE. 
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expression.  I expected that the Wnt treatment would result in an increase of either 
KCNQ1 or KCNQ1OT1, suggesting that this enhancer region is regulating the expression 
of that particular gene.  Based on my RT-qPCR results, the gene that appears to be 
regulated is KCNQ1 (Figure 25).  It appears that KCNQ1 expression matches the 
expression seen in the reporter assay, with increased expression in the Wnt treatment. I 
also tested β-catenin, KCNQ1OT1, and CDKN1C, one of the genes reported to be 
regulated by KCNQ1OT1.  β-catenin and CDKN1C were not significantly changed 
between Wnt and no Wnt treaments, but KCNQ1OT1 was significantly decreased in the 
presence of Wnt, which was the opposite of what we expected.   
 
Figure 25: RT-qPCR data from HEK293 cells treated with Wnt and no Wnt media. Each value 
has been normalized to 18S, and then to the no Wnt control. P values were obtained from a 2-
tail T-test. Error bars are standard deviation. 3 replicates.   
p=.250 p=.036 
p=.014 p=.949 
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Evaluation of enhancer target using Hi-C platform 
On Dr. Slattery’s advice I also used a Hi-C database browser to create virtual 4C 
(circularized chromosome conformation capture) data to look at the interactions of this 
enhancer within this gene domain (Figure 26).  This browser allows you to input a 
specific genetic location, and examine the interactions that sequence has with the 
surrounding DNA.  This interaction data is collected by first fixing cellular DNA with 
formaldehyde.  This crosslinks the DNA into its 3D conformation, keeping interacting 
regions of DNA together (Figure 26).  The DNA is then cut throughout with restriction 
enzymes (Figure 26).  This will allow isolation of the crosslinked sections of DNA 
(Figure 26).  The crosslinked DNA ends are then connected via DNA ligase, after which 
the DNA is linearized (Figure 26).  The data is then measured and analyzed for read 
length between cross linked segments: a shorter distance indicates that those two regions 
are interacting, a longer distance indicates that the two regions are not interacting (Figure 
26).   
The raw virtual 4C data was generated from HiC data collected in GM12878 
cells, a lymphoblastoid cell line.  The anchoring point is a 5 kb segment around our 
Figure 26: 4C data collection protocol to determine interactions between regions of DNA.   
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enhancer region.  The middle peaks are artifacts from the Hi-C assay, as DNA close to 
the anchoring point will normally have more interactions.  The peaks of importance are 
the ones annotated by the asterisks (Figure 27).  This 4C chart suggests that our region of 
interest is interacting with either the upstream gene region near the KCNQ1 gene, or the 
downstream gene region near CDKN1C.  I saw the same trend in several other cell types 
including mammary epithelia cells, umbilical vein endothelial cells, lung fibroblast cells, 
bone marrow lymphoblast cells, chronic myelogenous leukemia cells, and human 
epidermal keratinocyte cells.   
 To remove some of the inherent errors from the raw virtual 4C data, such as the 
central artifact peaks, we generated normalized virtual 4C data, which is thought to be 
more trustworthy than raw virtual 4C data.  The normalized virtual 4C data analyzed with 
the assistance of Dr. Slattery indicated one main peak of interest, located around 
2,900,000 bp (Figure 28).  This peak falls within the region of several genes: CDKN1C, 
SLC22A18, and PHLDA2.  All of these genes fall within the KCNQ1OT1 domain and are 
thought to be regulated by KCNQ1OT1 (Higashimoto, Soejima, Saito, Okumura, & 
Mukai, 2006).  CDKN1C specifically has been strongly suggested to be down regulated 
by KCNQ1OT1 (Chiesa et al., 2012).  Therefore, CDKN1C mRNA expression was tested 
using RT-qPCR along with the other genes previously examined: KCNQ1, KCNQ1OT1, 
and β-catenin (Figure 25).  However, CDKN1C expression was not significantly altered 
in the presence of Wnt.  Therefore, CDKN1C is not regulated by the Wnt-responsive 
component of this enhancer but may be regulated by another part of this region. 
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Figure 27: Virtual 4C database readout, raw calculation. 
Cell line used was GM12878, a lymphoblastoid cell line. X 
axis is the genome location, Y is the number of number of 
hits in that particular location.    
Figure 28: Normalized virtual 4C data generated from 
GM12878 cells. X axis is the genome location, Y is the 
number of number of hits in that particular location.    
   
* 
* * 
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To further attempt to understand the interactions occurring between KCNQ1, β-
catenin, and KCNQ1OT1, I conducted a literature search of Chip-Seq data to determine 
where β-catenin was known to bind, and if it bound specifically to KCNQ1 or to 
KCNQ1OT1.  However, I found that β-catenin binds to both the promoter of KCNQ1 and 
also to KCNQ1OT1 (Rapetti-Mauss et al., 2017); (Sunamura et al., 2016).  Therefore, it 
appears that β-catenin may regulate both KCNQ1 and KCNQ1OT1 expression.   
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Discussion  
Summary 
Regulation of KCNQ1 by KCNQ1OT1 
There are several conclusions that I was able to make from my experiments 
investigating the relationship between KCNQ1, KCNQ1OT1, and β-catenin expression in 
colorectal cancer cell lines.  Based on current understanding of the KCNQ1OT1 long non-
coding RNA from human Beckwith-Wiedemann syndrome data, KCNQ1OT1 is thought 
to downregulate the genes within its region, including KCNQ1 (Valente et al., 2019).  
However, it has also been suggested that KCNQ1 expression is independent of 
KCNQ1OT1 is expression, at least in the developing heart (Korostowski et al., 2012).  
Therefore, it can be concluded that the expression of KCNQ1OT1 may be tissue and 
development-stage specific, and that the downregulation of the genes within this domain 
is not universal.  I sought to try to clarify the role of KCNQ1OT1 in our system, 
colorectal cancer.  I hypothesized that KCNQ1OT1 down regulated KCNQ1.  To test this 
hypothesis, I compared the gene expression of two colorectal cancer cell lines: T84 and 
SW480.  These cell lines have differential methylation of the KCNQ1OT1 long non- 
coding RNA.  SW480 has both alleles unmethylated, T84 has one allele methylated and 
one allele unmethylated.  Therefore, I would expect higher expression of KCNQ1OT1 in 
the SW480 cells and lower expression of KCNQ1OT1 in the T84 cells.  I also wanted to 
examine the expression of KCNQ1 in these two cell lines.  If KCNQ1OT1 down regulates 
the expression of KCNQ1, then I would expect higher expression of KCNQ1 in the T84 
cells, and lower expression of KCNQ1 in the SW480 cells.  However, my results were not 
as I expected.  The KCNQ1OT1 expression did not appear to be altered between the two 
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cell lines, and although the KCNQ1 mRNA expression was different between the two cell 
lines, the trend was in the opposite direction than the one I had expected: KCNQ1 
expression was low in the T84, and higher in the SW480 cells (Figure 11).     
These results tell us that factors other than promoter methylation influence the 
expression of KCNQ1OT1 and that factors other than KCNQ1OT1 influence the 
expression of KCNQ1. 
To look directly at the role of KCNQ1OT1 I used siRNA in SW480 cells.  
However, the knockdown of KCNQ1OT1 was unsuccessful (Figure 11), probably 
because the cytoplasm-acting siRNAs were not able to reach and successfully 
knockdown the expression of nuclear-localized KCNQ1OT1.  It is also possible that the 
KCNQ1OT1 siRNA oligos were not targeting KCNQ1OT1 accurately.     
Therefore, we tried to deplete KCNQ1OT1 expression by knocking down β-
catenin.  β-catenin has been reported to promote KCNQ1 expression in colorectal cancer 
cell lines and siRNA knockdown of β-catenin has been used experimentally to 
knockdown expression of KCNQ1OT1 in these lines. 
Knockdown of β-catenin in colorectal cancer cell line SW480 yielded the same 
results.  β-catenin was effectively depleted. KCNQ1OT1 expression was diminished 
confirming that in these cell lines β-catenin promotes KCNQ1OT1 expression.  However, 
KCNQ1 expression remained unchanged (Fig 14). This result may indicate that neither 
KCNQ1OT1 or β-catenin affects KCNQ1 expression in these cell lines or that that these 
two factors have opposing effects with KCNQ1OT1 downregulating and β-catenin 
upregulating expression. 
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KCNQ1 putative enhancer region  
An unbiased examination of KCNQ1 genomic sequence identified a putative 
enhancer region in intron 2.  This enhancer of 614bp contains a SNP that shows 
differential KCNQ1 expression that falls in a DNase hypersensitive region.  This region 
also contains a TCF7L2 binding site.  Therefore, I hypothesized that this region might 
mediate Wnt/ β-catenin regulation of KCNQ1 expression.  To test this hypothesis, I 
evaluated the enhancer activity of this region and elements of it using a luciferase 
reporter assay. I created four reporter constructs: TCF7L2, TDHS-C, TDHS-T, and TE 
which were transiently transfected into HEK293 cells.  After treatment with Wnt or 
vehicle control, cells were evaluated for luciferase activity. The TCF7L2 binding site 
construct showed the strongest upregulation of luciferase signal in. response to Wnt.  
The full-length construct, TDHS, with either SNP polymorphism also showed a 
strong response to Wnt, however this response was ~30% lower than that of the TCF7L2 
site alone.  The region downstream of the TCF7L2 site showed no response.  These 
results indicate the enhancer region is an active regulatory site that mediates Wnt/ β-
catenin signaling.  However, the full-length region appears to contain an additional site 
that inhibits this signaling (Figure 24).  KCNQ1OT1 lies with the KCNQ1 gene and 
elements in KCNQ1 intron 2 are reported to regulate KCNQ1OT1 (Asahara et al., 2015).  
Further, if β-catenin was found to upregulate KCNQ1OT1 this might explain the 
downregulation of KCNQ1 in poor prognosis colorectal cancer.    
Therefore, I investigated whether our putative enhancer region regulated KCNQ1 
or KCNQ1OT1. Analysis of gene expression in HEK293 cells (the cell line used for the 
reporter assay) treated with Wnt or vehicle control showed that Wnt treatment promoted 
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transcription of KCNQ1 but not KCNQ1OT1 in these cells and so the reporter assay 
reflects upregulation of KCNQ1 by Wnt/ β-catenin signaling.  There was no increase in β-
catenin transcripts presumably because Wnt signaling acts primarily to stabilize β-catenin 
protein.   
To look at enhancer interactions in an unbiased fashion I carried out an in silico 
analysis of chromatin interaction using the Hi-C database to create a virtual 4C map.  4C 
data maps the interactions between a certain anchor site within DNA, in this case the 5kb 
region surrounding our enhancer and other genes by crosslinking the interacting DNA 
(Figure 25, 26).  This allowed me to obtain a prediction of where this enhancer region 
was interacting within the KCNQ1 and the KCNQ1OT1 domain.   
The normalized virtual 4C data had a high number of hits in one main location: a 
region downstream of our enhancer region, near the gene CDKN1C, a gene 
downregulated by KCNQ1OT1, which encodes a cyclin-dependent kinase inhibitor 
(Higashimoto et al., 2006).  This region also included the genes SLC22A18, and PHLDA2 
which are also downregulated by KCNQ1OT1.  However, Wnt treated HEK293 cells did 
not show upregulation of CDKN1C.  The Hi-C data were obtained from GM12878 not 
colorectal cancer cell lines.  However, these results support the hypothesis that this 
enhancer region is involved in transcriptional regulation of KCNQ1OT1 targets in a non-
Wnt-dependent fashion.   
 
Conclusions 
 I initially set out to test the hypothesis that KCNQ1 was down regulated by 
KCNQ1OT1.  I was not able to directly test this idea, and I did not uncover any evidence 
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supporting this. 
However, two different studies provided suggestive evidence that Wnt/ β-catenin 
promotes KCNQ1 expression.  First, data shown in Figure 14 show that decreased levels 
of KCNQ1OT1 fail to cause an increase in KCNQ1 levels when β-catenin is depleted 
suggesting that β-catenin may promote KCNQ1 expression in this context. Second, 
evaluation of a novel putative enhancer indicates that this enhancer also promotes 
KCNQ1 expression via Wnt/ β-catenin signaling.  However, the physiological 
significance of these findings remains to be determined. 
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Chapter 2: Kcnq1 and Cftr effect on β-catenin activity 
Examining β-catenin localization in organoid 3D cultures 
 
Materials and Methods 
Colon Organoid Preparation 
 Mice were euthanized according to IACUC specifications with CO2.  After the 
mouse was confirmed dead by toe pinch, the abdominal cavity was opened by pinching 
the skin between two fingers, making a V-shaped cut, and pulling apart to rip the skin 
away from the peritoneum.  This was repeated with the peritoneum in the same manner to 
reveal the intestines.  The colon was removed by removing fat and mesentery tissue and 
cutting below the cecum and just above the anus. The colon was washed in PBS before 
processing. 
 The colon was cut longitudinally using special intestine scissors that have one 
blunt end, to avoid tearing the intestine.  This blunt end was inserted into the colon and 
the intestine was cut open.  The colon was washed in a petri dish with PBS and repeated 
with a fresh PBS containing petri dish.  The colon was sectioned into small pieces, small 
enough to be pipetted in a 10ml pipette, using a razor blade, and transferred into a 50ml 
conical tube containing 10ml ice cold PBS.  
 The colon was washed in this 10mls of ice-cold PBS by pipetting up and down 
three times using a 10ml pipette, first coated with BSA to prevent sticking of the 
intestinal pieces to the inside of the pipette.  After three washes, the pieces were allowed 
to settle for ten- thirty seconds, and as much PBS as possible was removed from the 
conical tube.  The tube was then refilled with another 10ml of PBS, and this wash step 
was repeated twenty times.  The purpose of this step is to dislodge all single cells and 
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debris, while keeping the crypts attached to the intestinal pieces.  To loosen the crypts 
from the intestinal pieces, the tissue pieces were resuspended in 25ml of Chelation Buffer 
with 125µl of EDTA and put on a rotator for 70 minutes at 4°C.  The tissue pieces were 
allowed to settle, and the supernatant was removed.  10ml of Chelation buffer was added 
to the intestinal pieces, and the entire volume was pipetted up and down three times with 
a strong pipette, to induce mechanical shearing of the tissue.  After the pieces settled, 
10µl of the Chelation buffer (which should contain crypts) was placed on a slide to count 
the number of crypts present in each wash.  Each wash step with crypts was saved in a 
new 50ml conical tube.  This wash step was repeated until approximately 50ml of washes 
had accumulated, or until crypts were not present when wash buffer was observed under 
the microscope.  
 To prepare crypts for plating in Matrigel (growth factor reduced, phenol red free; 
BD Biosciences), the crypt-containing Chelation buffer was centrifuged at 300xg for five 
minutes at 4°C.  The supernatant was removed using a glass Pasteur pipette connected to 
a vacuum system.  The crypt pellet was resuspended in five to 10ml ADF (Advanced 
DMEM F12) media, with 1X Glutamine, 1X HEPES.  The crypt solution was counted on 
a hemocytometer: 20µl of media was placed on the grid portion of the hemocytometer 
without a coverslip present.  The crypts were counted, and calculations were done to 
determine volume of crypt solution needed to have a concentration of 3,000 crypts/ row 
of six wells.  
 The organoid solution necessary for my chosen concentration was placed in a new 
15ml conical tube, and centrifuged at 300xg for five minutes, at 4°C.  The supernatant 
was removed, and placed on ice, with previously thawed Matrigel.  The crypt pellet was 
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resuspended in 80µl of ADF and 120µl of Matrigel.  The resuspended crypts were plated 
quickly onto a pre-warmed 24 well tissue culture treated plate and let incubate at 37°C at 
5% CO2 for twenty minutes, to allow matrigel to harden.  500µl ADF media (with 
organoid supplements: HEPES, L-Glutamine, RSPO1, EGF, Noggin, B27, N2, N-
Acetylcysteine, and Primaxin) was added to each well, and plate was placed back in 
incubator. 
Passaging Organoids 
 To dissolve the matrigel, 500 µl cell recovery solution (Corning, Cat. No. 
354253) was added to each well.  After one hour, the matrigel was scraped off the bottom 
of the plate using a 1000µl pipette tip.  The cell recovery solution, now containing 
organoids and any undissolved matrigel, was transferred to a 15ml conical tube and 10ml 
of ADF media (without organoid supplements) was added to the tube and well mixed.  
The organoids were centrifuged at 300xg for five minutes at 4°C.  The supernatant was 
removed via vacuum and resuspended in 1ml media.  A 2ml pipette was attached to a 10 
µl pipette tip, and the organoid solution was pipetted up and down fifteen times to break 
organoids up into smaller pieces.  The organoid solution was centrifuged once more at 
the same settings, and the supernatant was removed.  The organoids were plated in 
Matrigel as done before.  
Immunofluorescent Cytochemistry for Organoids  
 This protocol was adapted from the paper Immunofluorescent staining of mouse 
intestinal stem cells (O’Rourke et al., 2016).  Organoids were passaged, and plated in a 
FluoroDish (World Precision Instruments, Cat. No. FD35-100) and incubated at 37°C at 
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5% CO2 for 24 hours in Wnt-free media (Figure 29).  The organoids were fixed in 4% 
paraformaldehyde (PFA) in PME buffer for twenty minutes.  The PFA was removed, and 
the organoids were rinsed in 200µl IF buffer (.2% Triton X-100, .05% Tween), then 
twice in 200µl ice cold PBS.  200µl permeabilization buffer (1% saponin, 1% Triton X-
100 in PBS) was added to the organoids and let incubate for twenty minutes at RT.  The 
permeabilization buffer was removed, and the organoids were again rinsed twice in 200µl 
ice-cold PBS (Figure 29).   
The organoids were prepared for the antibody step by blocking with 200µl 
blocking buffer (5% BSA, .5% gelatin, .05% Tween in PBS) for one hour at room 
temperature.  The blocking buffer was removed and 40 µl β-catenin antibody (Alexa 
Fluor 488 Mouse anti- β-catenin, Cat# 562505) (1:9, antibody: blocking buffer) was 
added to the organoids.  The organoids were kept from light at 4°C overnight (Figure 29). 
Figure 29: Immunofluorescent staining protocol for 3D organoid cultures.   
 
 
 
 
 57 
The antibody was removed, and organoids were rinsed three times in ice cold 
PBS.  Each wash was kept for five minutes each.  30µl of 1µg/ml DAPI nuclear stain was 
added to the organoids, and they were incubated in dark for twenty minutes.  DAPI was 
removed, and organoids were rinsed with IF buffer, and all liquid was removed.  The 
organoids were rinsed with MillQ water, and all liquid was removed using the edge of a  
Kimwipe.  A coverslip was then coated with a thin layer of Prolong Gold Antifade 
(P36930, Thermo Fisher) and placed carefully onto of the organoids on the bottom of the 
Fluorodish.  The organoids were incubated overnight at 4°C, and imaged on a LSM 710 
confocal microscope the next day (Figure 29).   
A coverslip was then coated with a thin layer of Prolong Gold Antifade (P36930, 
Thermo Fisher) and placed carefully onto of the organoids on the bottom of the 
Fluorodish.  The organoids were incubated overnight at 4°C, and imaged on a LSM 710 
confocal microscope the next day (Figure 29).   
Analysis of Nuclear β-catenin in organoids 
To analyze the expression of nuclear β-catenin, I circled each nuclei using ImageJ 
software, and identified each as a region of interest.  The nuclei localization was 
determined via the DAPI signal.  I measured the mean intensity of DAPI in each nuclei.  I 
switched to the other channel which had the β-catenin signal and measured the mean β-
catenin intensity within each same region of interest.  I divided each nuclei’s β-catenin 
signal by the DAPI signal to normalize between organoids.  Each nuclei ratio was then 
averaged, yielding one value per organoid, and approximately 5-7 organoids were 
measured for each treatment group.  These values were again averaged, and the KO value 
was then divided by the WT value to get an overall ratio representing the difference 
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between the KO and WT organoids.  Three biological replicates were done for each, and 
2-tailed T-tests were utilized to determine significance.   
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Results 
 Because of the importance of Wnt- β-catenin signaling in colorectal cancer 
development I evaluated the effect of Kcnq1 and Cftr deficiency on this signaling 
pathway.  To examine the role of β-catenin within the complex stem cell 
microenvironment, I decided to look at β-catenin activity in stem cell compartment 
organoid cultures.  Translocation of β-catenin from the cytoplasm to the nucleus is a key 
regulatory step in transcriptional activation.  Therefore, I devised a way to measure and 
quantify the amount of β-catenin within the nucleus of the colon organoids, to better 
understand how Kcnq1 and Cftr affect β-catenin activity.  
 
Protocol development 
 It is not practical to analyze protein expression in organoids because the of the 
limited amount of material available, so I developed a quantitative immunocytochemistry 
method.  However, because organoids are large 3D structures many layers of 
troubleshooting were required to develop this protocol for our lab.   This protocol 
development was done in collaboration with Dr. Cara Hegg of the Whiteside Institute for 
Clinical Research. 
 Initial attempts using DAPI to stain nuclei resulted in collapsed organoids (Figure 
30).  My protocol at this point involved plating the organoids in Fluorodishes, fixing 
them immediately, and proceeding with the permeabilization, blocking, and treatment 
with DAPI for nuclear staining.  We hypothesized that organoids might be losing their 
structure due to stress from being plated and then immediately fixed and treated.  Adding 
a 24 hour incubation period after plating the organoids before fixation helped the  
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organoids maintain their structure throughout the fixing and subsequent treatments.    
Organoids treated in this way appeared much healthier and maintained a more spherical 
shape (Figure 31).   
Figure 31: Organoids fixed 24 hours after plating. Spherical shape is 
maintained. Magnification is 40X. Scale bars are 50μm. 
Figure 30: A) First attempt of IFC staining of organoids. Too much DAPI 
was used, but the loss of spheroid structure is evident. Magnification is 
10X. B) Less DAPI was used for next attempt, but again spheroid 
structure was lost during procedure. Magnification is 25X. Scale bars are 
50μm 
. 
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Next, I wanted to optimize the DAPI stain in the organoids, as DAPI nuclear 
staining did not appear uniform throughout the organoid with a DAPI treatment of 2 
minutes.  However, DAPI staining appeared to be uniform in a time range from 2 to 30 
minutes (Figure 32).   
Once the organoids were maintaining their structure throughout the 
immunofluorescent protocol, I developed the conditions for β-catenin signaling. To 
specifically detect nuclear localized β-catenin organoids treated with Wnt-conditioned 
Figure 32: Optimization of DAPI staining time A) 2 minutes of DAPI treatment. 
B) 8 minutes of DAPI treatment. C) 16 minutes of DAPI treatment. D) 30 minutes 
of DAPI treatment. DAPI appears to be staining equally well from 2 minutes up to 
30 minutes. Magnification is 40X. Scale bars are 50μm. 
 62 
media were compared to untreated controls.  In initial experiments the β-catenin signal 
was weak and no nuclear staining was detected. (Fig. 33)  
Figure 33: First attempt of staining the organoids with β-catenin. Organoids were 
treated with media containing Wnt conditioned media or no Wnt media. 
Although DAPI staining appears strong, the β-catenin antibody does not appear 
to staining strongly, and no β-catenin is visible in the nucleus in the presence of 
Wnt as I expected. Magnification is 40X. Scale bars are 50μm. 
Figure 34: Organoids treated with new saponin permeabilization step. 
Magnification is 40X. Scale bars are 50μm. 
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To address this problem, I increased the concentration of the permeabilization 
agent (Triton-X100) and added a second detergent, saponin, to my permeabilization 
buffer.  This improved the β-catenin signal (Figure 34).  To develop a control with more 
Figure 35: Organoid with no treatment for control. Organoids treated 
with Wnt containing media and GSK3 inhibitor CHIR990221. With this 
treatment, a significantly higher amount of nuclear β-catenin is observed. 
Three replicates were done, p value was obtained from a two tailed t-test. 
Magnification is 40X. Scale bar is 50μm. 
 
No 
treatment 
p= .005 
Wnt/ 
GSK3 
inhibitor 
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robust nuclear signaling I treated organoids with Wnt and a GSK3 inhibitor, CHIR99021 
(Sigma, SML1046).  GSK3 is a member of the complex involved in cytoplasmic 
destruction of β-catenin, preventing its translocation into the nucleus (Figure 4).  As 
expected, the nuclear β-catenin was detectable (Figure 35).   
 However, as Apc is known to be one of the key regulators of β-catenin in 
colorectal cancers, I wanted to establish that our protocol would detect the movement of 
β-catenin into the nucleus of the organoids with a lack of Apc.  Therefore, I used 
organoids generated from mice developed by Dr. Cormier containing a conditional 
homozygous Apc deletion (ApcFl/Fl) a conditional Luciferase reporter gene (LSL-Luc) and 
a tamoxifen inducible Cre recombinase (CreERT2).  Kyle Anderson generated organoids 
were from uninduced mice. Loss of Apc and activation of luciferase were induced by 
tamoxifen treatment.  To verify that Apc excision was successful luciferase signaling was 
visualized (Figure 36).  Nuclear β-catenin localization was significantly increased in the 
Apc low organoids compared to the Apc high organoids (Figure 37).   
   
Figure 36: 2 wells of mutated organoids, treated with tamoxifen to induce Apc KO. 
Organoids are expressing luciferase indicating that they have been successfully 
mutated and are indeed Apc KO.  
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Examining β-catenin localization in organoid 3D cultures 
 
Now that I had established that my protocol detects nuclear β-catenin with 
treatments that should induce this localization, I began testing our Cftr KO and WT 
organoids, as well as the Kcnq1 KO and WT organoids to determine localization of β-
catenin with and without these tumor suppressors present.  
Figure 37: Nuclear β-catenin in Apc low and Apc high organoids. Nuclear β-catenin is 
significantly higher in Apc low organoids compared to the Apc high organoids. Three 
replicates, p value obtained from a two tailed t-test. Magnification is 40X. Scale bar is 
50μm. 
 
p= .009 
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 As Cftr and Kcnq1 are tumor suppressors: lower Cftr and Kcnq1 expression is 
associated with poor patient prognosis.  Therefore, I would expect that with low Cftr and 
Kcnq1 expression nuclear β-catenin would increase.   
 The Cftr and Kcnq1 organoids were treated for 24 hours without Wnt before 
fixing and staining.  Organoids isolated from colons are dependent on β-catenin for 
survival and are maintained in Wnt-containing media.  Therefore, as we wanted to look 
as the basal β-catenin differences between the two, we removed the β-catenin from both 
before fixing to allow for any differences present to be detected.  The Cftr and Kcnq1 
organoids yielded expected results.  I observed an increase in nuclear β-catenin 
expression in the Cftr KO organoids (Figure 38).  I also observed a statistically 
significant increase in nuclear β-catenin in the Kcnq1 KO organoids compared to the WT 
organoids (Figure 39).  These data suggest that Kcnq1 and Cftr regulate β-catenin 
activity.  This could potentially be the mechanism by which Kcnq1 and Cftr act as tumor 
suppressors.  This is the only data done in a colon system, providing a very biologically 
relevant model for understanding the regulation of β-catenin in the colon.   
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Figure 38: Organoids with high Cftr and low Cftr expression. Values 
are relative nuclear β-catenin, normalized to DAPI signal. p-value is 
from 2-tailed t-test. Magnification is 40X. Scale bar is 50μm. 
 
 
p= .057 
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Figure 39: Organoids with high Kcnq1 and low Kcnq1 expression. 
Quantification values are relative nuclear β-catenin, normalized to DAPI 
signal. p-value is from 2-tailed t-test. Magnification is 40X. Scale bar is 
50μm. 
p=.0195 
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Discussion  
Summary 
 Because of the importance of the Wnt/ β-catenin pathway in colorectal cancer I 
wanted to determine if Kcnq1 or Cftr played a role in this pathway.  Immunofluorescent 
analysis of Cftr KO organoids revealed increased nuclear β-catenin compared to the WT 
organoids.  The immunofluorescent staining of Kcnq1 KO organoids with β-catenin 
revealed significantly increased nuclear β-catenin compared to WT.  It suggests that 
Kcnq1 and Cftr may act as tumor suppressors through their regulation of β-catenin 
activity.  As β-catenin is one of the major drivers of colorectal cancer, this is an important 
observation. 
Our research was done in an organoid system.  As Cftr and Kcnq1 are both 
expressed in the intestinal crypt base, the site of the stem cell compartment and the site of 
origin for colorectal cancer, looking at these factors in organoids is biologically 
significant.  Much of the research done on Kcnq1 and β-catenin and Cftr and β-catenin 
has been done in cell lines.  Cell lines are not necessarily an accurate model for colorectal 
cancer due to their 2D structure and monoclonality.  They are transformed and typically 
derived from cancer tumors.  Our organoids have many advantages compared to cell 
lines.  Organoids provide a 3D model of cell structure, creating a more accurate 
representation of the cellular microenvironment.  Organoids are heterogeneous, with stem 
cells and other cells forming a spheroid with a lumen at the center.  The organoids are 
also a non-transformed cancer model, proving an accurate model for basal interactions 
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within the stem cell compartment.   Therefore, our data in organoids is relevant to the 
question we are trying to address.    
These results help to address the question of how Cftr activity affects the nuclear 
localization of β-catenin in the normal colon epithelium which may be relevant for the 
development of colorectal cancer.  Our results are consistent with previous work in which 
Cftr deficiency correlated with increased β-catenin transcriptional activity in small 
intestinal adenomas (Than et al., 2014) and crypts and organoid cultures (Strubberg et al., 
2018). There has also been a report of Cftr deficiency associated with decreased β-catenin 
transcriptional activity (Lui et al., 2017).  The discrepancy may be due to the fact that this 
study measured activity in whole intestinal tissue (Strubberg et al., 2018).  Our data is the 
only data in colon organoids which is very biologically relevant and will add clarity to 
the question of interactions between Cftr and β-catenin in the intestinal stem cell 
compartment (Figure 40). 
 
Figure 40: Interactions between Cftr and β-catenin in 
intestinal models including my organoid data.  
 71 
 These results also address the question of how Kcnq1 activity affects the 
transcriptional activity of β-catenin. Our results demonstrate that Kcnq1 deficiency 
promotes nuclear localization of β-catenin however the mechanism is unknown (Figure 
41). Harvey and colleagues report that KCNQ1 promotes the membrane sequestration of 
beta catenin (Harvey et al., 2017).  It remains to be determined if release of β-catenin into 
the cytoplasm is sufficient for increased nuclear localization. 
 
  
Conclusions 
  Cftr and Kcnq1 appear to regulate β-catenin activity.  This suggests a mechanism 
for the tumor suppressor role of Cftr and Kcnq1 in the intestinal stem cell compartment.  
Our results were obtained in colon organoids, which is a novel system for these 
observations, and arguably the most biological relevant one for the study of the basic 
Figure 41: Interactions between KCNQ1, KCNQ1OT1, 
and β-catenin in intestinal models, and my data from 
organoids and the reporter assay  
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interactions in the colon.  Studying these interactions in a non-cancer model is important 
in the study of colorectal cancer, to more fully understand the basic mechanisms at play 
within the intestinal stem cell compartment before cancerous mutations occur. 
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Appendix 
Introduction 
The unfolded protein response, activated by the presence of unfolded proteins 
within the ER, induces three pathways (Grootjans et al., 2016).  When a protein is 
misfolded, the binding immunoglobulin protein (BiP) dissociates from IRE1-alpha, or the 
misfolded protein may bind IRE1-alpha directly (Figure 42).  This induces the splicing of 
XBP1u (unspliced X-box binding protein), resulting in the activation of XB1s, 
transcription activators (Figure 41). These transcription factors activate proteins to assist 
with protein folding, as well as ERAD (ER-associated degradation) protein, which assists 
in the degradation of misfolded proteins from the ER (Figure 42).  The second pathway is 
induced when a misfolded protein binds the PERK protein, inhibiting elF2- α (eukaryotic 
translation initiation factor 2 α).  PERK also induces the movement of transcription 
factor ATF4 into the nucleus, where it activates expression of genes for anti-oxidant 
Figure 42: Unfolded protein response, demonstrates the three pathways initiated in 
the presence of misfolded proteins (Grootjans, Kaser, Kaufman, & Blumberg, 
2016). 
 74 
response, apoptosis, and autophagy (or self-eating: a mechanism wherein a cell 
destroys organelles or other cellular components (Grootjans et al., 2016).  The third 
pathway involves binding from the misfolded proteins to a factor called ATF6, 
inducing the movement of transcription factor ATF6p50 to the nucleus, where it 
induces the expression of XBP1, ERAD, and more chaperone proteins (Grootjans, et 
al., 2016).  The unfolded protein response helps the cell to cope with ER stress produced 
by unfolded proteins, and this remains an important area of research in the field to better 
understand the role of CFTR within the cell microenvironment. 
Materials and Methods 
 The colorectal cancer cell line Caco2 was obtained from ATCC.  These cells 
were modified via the CRISPR-Cas9 gene editing system to knockout the CFTR gene on 
both alleles for a homozygous KO.  To use as a WT cell line, Caco2 cells were treated 
with a non-targeting CRISPR-Cas9 gene editing.  All experiments were conducted using 
these CFTR KO (D8) and a CFTR WT (Y21) cell lines.   
MTT Assay 
The Y21 and D8 cells were plated at 4,000 cells/well in a 96 well plate and 
incubated 37°C for 24 hours.  The cells were then treated with .1uM Thapsigargin 
(Catalog # T9033, Sigma-Aldrich) to induce the UPR (Chidawanyika, Sergison, Cole, 
Mark, & Supattapone, 2018).  The cells were treated with the MTT reagent at various 
time points.  MTT dye is reduced by NAPDH-reductase enzymes, resulting in production 
of insoluble, purple-colored formazan (Pascua-Maestro et al.,  2018), giving an indication 
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of cell viability at different points after the treatment. After four hours, a solubilization 
reagent was added, and the cells were incubated overnight before being read on a plate 
reader for absorbance at 595nm, and then read for background at 660nm.  The MTT dye 
was added to five different plates at varying timepoints: 2 hours, 24 hours, 48 hours, 72 
hours and 96 hours.  All time points were normalized to an untreated, 0 hour plate to 
account for differences in growth between the two different cell lines. 
SRB Assay 
 The cells were plated at 4,000 cells/well in a 96 well plate and incubated at 37°C 
for 24 hours.  The cells were then treated with .1uM Thapsigargin (Catalog # T9033, 
Sigma-Aldrich) to induce the UPR (Chidawanyika, Sergison, Cole, Mark, & 
Supattapone, 2018).  The cells were then fixed, at various time points, using ice-cold PBS 
for approximately 10 minutes.  The cells were placed in a dry incubator at 37°C for 1 
hour to dry completely.  At this point, the plate can be left at room temperature 
indefinitely until the next step.  The cells were treated with 50ul of .04% SRB solution in 
1% acetic acid and incubated at room temperature for 1 hour.  The cells were rinsed 3X 
with 1% acetic acid to remove excess SRB solution.  SRB binds to protein, and provides 
an indication of cellular protein content, and therefore cell density (Vichai & Kirtikara, 
2006).  The plates were dried in the dry incubator for 1-2 hours, or until all liquid has 
evaporated.  At this point, the plate can be left at room temperature indefinitely until the 
next step.  The cells were treated with 100ul of 10M Tris and incubated for 5 minutes to 
resuspend the SRB with their bound proteins.  The cells were read on a plate reader at 
540nm to measure the absorbance of the SRB signal.  Similar to the MTT assay, the SRB 
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assay was started on five different plates at various times after treatment: 2 hours, 24 
hours, 48 hours, 72 hours and 96 hours.   
Results 
CFTR KO/WT Cells Response to ER Stress through Unfolded Protein Response  
 To determine the role of CFTR in the unfolded protein response due to ER stress, 
I ran MTT and SRB assays to measure the viability and protein concentration in CFTR 
WT and KO cell lines after treatment with Thapsigargin, which induces ER stress.   
The MTT assay revealed a significant difference between the CFTR KO and WT 
cell lines at several of the time points (Figure 43). The SRB assay revealed a similar 
trend, although the significant time points were slightly varied from the MTT assay 
(Figure 43).   
Figure 42: MTT assay, with Y21 (CFTR WT) and D8 (CFTR KO) Caco2 cell lines, 
treated with .1uM Thapsigargin to induce ER stress. CFTR KO cells have a 
significantly better survival compared to the CFTR WT. Three replicates, p values 
from 2-tailed T-tests  
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Figure 43: SRB assay, with Y21 (CFTR WT) and D8 (CFTR KO) Caco2 cell lines, 
treated with .1uM Thapsigargin to induce ER stress. CFTR KO cells have a 
significantly better survival compared to the CFTR WT at several time points. Three 
replicates, p values from 2-tailed T-tests  
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Additional  
RT-qPCR Primers 
18S 
Forward: 5’ CGCCGCTAGAGGTGAAATTCTT 3’ 
Reverse: 5’ CAGTCGGCATCGTTTATGGTC 3’ 
150bp  
 
KCNQ1 
Forward: 5’ GCGGAAGCCTTACGATGTG 3’ 
Reverse: 5’ CCTTGTCTTCTACTCGGTTCAGG 3’ 
200bp 
 
KCNQ1OT1 
Forward: 5’ TGGTCTGGTGGGCTTTTGTT 3’ 
Reverse: 5’ GGGACACAGGAGTGTAAGCC 3’  
128bp 
 
β-catenin (CTNNB1) 
Forward: 5’ TCTGATAAAGGCTACTGTTGGATTGA 3’  
Reverse: 5’ TCAGCGAAAGGTGCATGATT 3’ 
 
CDKN1C 
Forward: 5’ GTGAGCCAATTTAGAGCCCAA 3’ 
Reverse: 5’ CGGTTGCTGCTACATGAACG 3’ 
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